Bausch + Lomb Corporation announced its second-quarter 2025 financial results, reporting a revenue of $1.278 billion, reflecting a 5% increase as reported and a 3% rise on a constant currency basis compared to the same quarter in 2024. The company recorded a GAAP net loss attributable to Bausch + Lomb Corporation of $62 million. Adjusted EBITDA, excluding Acquired IPR&D (non-GAAP), was $192 million for the quarter. In terms of earnings per share, the adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP) was $0.07 for the second quarter of 2025, compared to $0.13 in the same period of 2024. The company has raised its full-year 2025 guidance to reflect solid business performance and the impact of foreign exchange, with full-year revenue foreign exchange tailwinds anticipated to be nominal. Operational highlights include the resumption of full production of all enVista® platform intraocular lenses following their return to the market. The company also reported reaching approximately $1 billion in trailing 12-month revenue across its dry eye portfolio and achieving broad-based growth in Vision Care, led by key contact lens franchises. Bausch + Lomb successfully executed a refinancing transaction, thereby extending its maturity profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.